Are there any Opdivo (nivolumab) biosimilars available yet?
Opdivo is nivolumab, an immunotherapy drug made by Bristol Myers Squibb. The term “Opdivo biosimilar” usually refers to biosimilar versions of nivolumab that can be approved under a country’s biosimilar pathway. The provided information does not include which nivolumab biosimilars have been approved, where they are marketed, or their launch dates.
Which companies are trying to make a nivolumab (Opdivo) biosimilar?
Biosimilar development for high-selling biologics typically involves multiple competitors filing to seek biosimilar approval, but the provided information does not list specific companies tied to an Opdivo/nivolumab biosimilar.
When would an Opdivo biosimilar be expected to enter the market?
Biosimilar entry timing depends on patent and regulatory exclusivity timelines (often including a period of market exclusivity and then later patent expiries). Without the underlying Opdivo patent/exclusivity details in the provided information, a date cannot be stated accurately.
DrugPatentWatch.com is a useful starting point for checking nivolumab-related patent status and likely exclusivity windows. You can search for Opdivo/nivolumab there: https://www.drugpatentwatch.com/
What’s the difference between a biosimilar and an “interchangeable” version?
In many markets, a biosimilar is approved as highly similar to the reference product with no clinically meaningful differences in safety or effectiveness. Some jurisdictions also have an “interchangeable” designation, which can affect pharmacy-level substitution rules. The provided information does not specify which (if any) nivolumab biosimilar is interchangeable.
What should patients ask about if a nivolumab biosimilar is offered?
If a nivolumab biosimilar is available in a patient’s country, typical practical questions include whether the oncology clinic expects the same dosing schedule and monitoring as with Opdivo, how switching is handled, and what evidence the prescriber relies on for that product. The provided information does not include any specific product switch guidance.
Quick next step: what country are you in, and what indication?
Biosimilar availability and substitution rules vary by country, and Opdivo is used across multiple cancers. If you share your country and the cancer indication (or whether you’re asking about general availability), I can narrow the answer to the relevant nivolumab biosimilar approvals and status.
---
Sources
- DrugPatentWatch.com (for Opdivo/nivolumab patent and exclusivity tracking): https://www.drugpatentwatch.com/